- Company
- Long-waited reimbursed Ibrance+Faslodex in arm’s reach
- by Eo, Yun-Ho Feb 20, 2020 06:42am
- After two long years, Pfizer is finally in proximity to win reimbursement on Ibrance plus Faslodex combination therapy. Pharmaceutical industry source reported, Drug Reimbursement Evaluation Committee (DREC), under Health Insurance Review and Assessment Service (HIRA), has cleared the combination therapy consisting of Pfizer’s CDK4/6 in
- Company
- Jeil·Hanlim’s authorized generics, challenge to the market
- by Nho, Byung Chul Feb 20, 2020 06:42am
- Circadin‘s authorized generics are expected to be released to the market as early as next month. According to the industry, Jeil, Hanlim, and CMG will release their products sequentially in March, April, and May through Kuhnil. The reason for launching Circadin‘s authorized Generics seems to be aimed at the market for the patent expi
- Company
- Ex-AstraZeneca personnel snatch up top executive positions
- by Lee, Seok-Jun Feb 20, 2020 06:35am
- Former employees of AstraZeneca are favored as top executives in Korean pharmaceutical companies. The positions vary from CEO to vice-president. Korea pharmaceutical companies are aiming to expand overseas business by recruiting former AstraZeneca employees with global experience. AstraZeneca is a British multinational company. At
- Policy
- MFDS reveals detailed clinical trial inspection plan
- by Lee, Tak-Sun Feb 20, 2020 06:35am
- Korea’s Ministry of Food and Drug Safety (MFDS) plans to conduct extensive inspection on clinical trial regarding pharmaceutical approval. The subjects are new drugs and drugs required to submit evidential data. Accordingly, pharmaceutical companies, CRO, and healthcare institutes would be investigated by Clinical Trial Management Division
- Opinion
- [FOCUS] Distrust caused by pharmaceutical and bio companies
- by Chon, Seung-Hyun Feb 20, 2020 06:34am
- Financial authorities again cut the disclosure of pharmaceutical and bio companies. The Korea Exchange prepared the 'Inclusive Disclosure Guidelines for Pharmaceuticals and Bio-Industry' and recommended that specific disclosure cases be followed and followed in accordance with industry characteristics. The intention is to encourage investors
- Company
- Remsima SC is the idea of CEO Jung-jin Seo
- by An, Kyung-Jin Feb 19, 2020 06:35am
- [Vienna, Austria=Reporter An, Kyung-Jin] On the 15th (local time), the annual meeting of the European Crohn's Disease Colitis Association (ECCO 2020) completed a four-day campaign. The ECCO 2020 Conference, which marks the 15th anniversary of this year, was a place to realize that K-Bio's technology has taken a step up. The launch of t
- Company
- New migraine preventive Emgality cleared in general hospital
- by Eo, Yun-Ho Feb 19, 2020 06:34am
- Korean general hospitals are swiftly implementing a new migraine preventive medication, Emgality, on their prescription drug code. According to a pharmaceutical industry insider, migraine-preventing calcitonin gene-related peptide (CGRP) antagonist Emgality (galcanezumab) has been launched last December. And it has been passed by Drug C
- MK-6482, the next rising anticancer drug is being developing
- by Won, jong-hyuck Feb 19, 2020 06:34am
- The development of the next generation of targeted anticancer drugs, which combines the Nobel Prize-winning theory with the field of chemotherapy, is entering the second half. The first is about the &8203;&8203;advanced renal cell carcinoma. Von Hippel-Lindau (VHL) works by the Dana-Farber Cancer Institute, winner of the 2019 Nobel Prize in
- Policy
- If the MFDS followed the EMA instead of the FDA for Belviq
- by Lee, Tak-Sun Feb 19, 2020 06:33am
- At the time of approving Belviq, banned by the MFDS on the 14th, it would be regrettable that it had not been approved in accordance with the European EMA's decision. The European EMA disagreed with the approval due to side effects from animal testing, and the developer voluntarily withdrew the application. The US FDA, on the other ha
- Company
- JW Holdings patent pancreatic cancer diagnostic kit in US
- by Nho, Byung Chul Feb 19, 2020 06:33am
- JW Holdings has also successfully patented an early-stage pancreatic cancer diagnostic technology in the U.S. JW Holdings (CEO Han Seong Gwon) announced on Feb. 17, the United States Patent and Trademark Office (USPTO) has granted a patent on source technology of the world’s first ‘multi-biomarker diagnostic kit’ that identifies pancr
